Interaction between polymorphisms in slc6a4 and bdnf on major depressive disorder in a sample of the argentinean population
Article Sidebar
Main Article Content
Abstract
The dysfunction in the serotoninergic neurotransmission has been classically associated with major depressive disorder (MDD); however, other pathways and processes seem to have a role in this illness, such as neurogenesis and related molecules: the Brain-Derived Neurotrophic Factor (BDNF) and the Apolipoprotein E (APOE). There are many reports that indicate an association between certain polymorphism in these genes and MDD. The aim of our study was to analyze the possible association between MDD and polymorphisms in HTR2A (5-hydroxytryptamine receptor 2A), BDNF and APOE genes in a sample of the Argentinean population previously studied for 2 polymorphisms in SLC6A4 (Solute Carrier Family 6 Member 4) gene. Five polymorphisms were studied (rs6311 and rs6313 in HTR2A; rs429358 and rs7412 in APOE, and rs6265 in BDNF) in 95 MDD patients and 107 non-related controls. No statistically significant differences were observed between groups when analyzing the association with a single marker using logistic regression; however, when a possible combinatory effect of the polymorphisms (including previously studied polymorphisms in SLC6A4 gene) was analyzed using a dominant model for the risk alleles, the genotypes L/S_10/12_G/A (OR=3.57(95%CI=1.43-8.93); p=0.004, adjusted p-value=0.01) in SLC6A4 and BDNF genes and L/S_10/12_T/C_3/3_G/A in SLC6A4, HTR2A, APOE and BDNF genes (OR=5.99(95%CI=1.66-21.56); p=0.002, adjusted p-value=0.07), were more prevalent in patients than in controls (20%vs.6% and 15%vs.3%, respectively). Even though it is necessary to replicate these findings in a larger population, our results suggest a possible interaction between molecules involved in neurogenesis (BDNF and APOE), serotoninergic neurotransmission (SLC6A4 and HTR2A) and the pathogenesis of MDD
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
Lesch KP, Balling U, Gross J, et al. Organization of the human serotonin transporter gene. J Neural Transm Gen Sect. 1994;95(2):157-162. DOI: https://doi.org/10.1007/BF01276434
Heils a, Teufel a, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem . 1996;66(6):2621-2624. DOI: https://doi.org/10.1046/j.1471-4159.1996.66062621.x
Hu X-Z, Lipsky RH, Zhu G, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet. 2006;78(5):815-826. DOI: https://doi.org/10.1086/503850
Van Dyck CH, Malison RT, Staley JK, et al. Central Serotonin Transporter Availability Measured with [123I]beta-CIT SPECT in Relation to Serotonin Transporter Genotype. Am J Psychiatry. 2004;161(3):525-531. DOI: https://doi.org/10.1176/appi.ajp.161.3.525
Uher R, McGuffin P. The moderation by the serotonin transporter gene of environmental adversity in the aetiology of mental illness: review and methodological analysis. Mol Psychiatry. 2008;13(2):131-146. DOI: https://doi.org/10.1038/sj.mp.4002067
Jaworska N, MacMaster FP, Foster J, et al. The influence of 5-HTTLPR and Val66Met polymorphisms on cortical thickness and volume in limbic and paralimbic regions in depression: a preliminary study. BMC Psychiatry. 2016 Mar;16:61. DOI: https://doi.org/10.1186/s12888-016-0777-x
Cajal AR, Redal MA, Costa LD, et al. Influence of 5-HTTLPR and 5-HTTVNTR polymorphisms of the serotonin transporter gene (SLC6A4) on major depressive disorder in a sample of Argentinean population. Psychiatr Genet. 2012;22(2):103-104. DOI: https://doi.org/10.1097/YPG.0b013e32834acc9b
Husain MM, McDonald WM, Doraiswamy PM, et al. A magnetic resonance imaging study of putamen nuclei in major depression. Psychiatry Res. 1991 Oct;40(2):95-99. DOI: https://doi.org/10.1016/0165-1781(91)90149-J
Fukuda Y, Koga M, Arai M, et al. Monoallelic and unequal allelic expression of the HTR2A gene in human brain and peripheral lymphocytes. Biol Psychiatry. 2006;60(12):1331-1335. DOI: https://doi.org/10.1016/j.biopsych.2006.06.024
Mattson MP, Maudsley S, Martin B. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci. 2004;27(10):589-594. DOI: https://doi.org/10.1016/j.tins.2004.08.001
Martinowich K, Lu B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology. 2008;33(1):73-83. DOI: https://doi.org/10.1038/sj.npp.1301571
Martinowich K, Manji HK, Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci. 2007;10(9):1089-1093. DOI: https://doi.org/10.1038/nn1971
Guilloux JP, Douillard-Guilloux G, Kota R, et al. Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression. Mol Psychiatry. 2012;17(11):1130-1142. DOI: https://doi.org/10.1038/mp.2011.113
Verhagen M, van der Meij A, van Deurzen PA, et al. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol Psychiatry. 2010;15(3):260-271. DOI: https://doi.org/10.1038/mp.2008.109
Chen ZY, Jing D, Bath KG, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science. 2006;314(5796):140-143. DOI: https://doi.org/10.1126/science.1129663
Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112(2):257-269. DOI: https://doi.org/10.1016/S0092-8674(03)00035-7
Eaton MJ, Staley JK, Globus MY, et al. Developmental regulation of early serotonergic neuronal differentiation: the role of brain-derived neurotrophic factor and membrane depolarization. Dev Biol. 1995; 170:169-182. DOI: https://doi.org/10.1006/dbio.1995.1205
Duman RS, Monteggia LM. A Neurotrophic Model for Stress-Related Mood Disorders. Biol Psychiatry. 2006; 59:1116-1127. DOI: https://doi.org/10.1016/j.biopsych.2006.02.013
Dalton ED, Hammen CL, Najman JM, et al. Genetic Susceptibility to Family Environment : BDNF Val66met and 5-HTTLPR Influence Depressive Symptoms. J Fam Psychol. 2014;28(6):947-956. DOI: https://doi.org/10.1037/fam0000032
Colle R, Gressier F, Verstuyft C, et al. Brain-derived neurotrophic factor Val66Met polymorphism and 6-month antidepressant remission in depressed Caucasian patients. J Affect Disord. 2015;175:233-240. DOI: https://doi.org/10.1016/j.jad.2015.01.013
Lopez-Leon S, Janssens AC, Gonzalez-Zuloeta Ladd AM, et al. Meta-analyses of genetic studies on major depressive disorder. Mol Psychiatry. 2008;13(8):772-785. DOI: https://doi.org/10.1038/sj.mp.4002088
Feng F, Lu S-S, Hu C-Y, et al. Association between apolipoprotein E gene polymorphism and depression. J Clin Neurosci. 2015;22:1232-1238. DOI: https://doi.org/10.1016/j.jocn.2015.02.012
Surtees PG, Wainwright NW, Bowman R, et al. No association between APOE and major depressive disorder in a community sample of 17,507 adults. J Psychiatr Res. 2009;43(9):843-847. DOI: https://doi.org/10.1016/j.jpsychires.2008.12.001
Kamboh MI. Apolipoprotein E polymorphism and susceptibility to Alzheimer’s disease. Hum Biol. 1995; 67(2):195-215.
Smith AD, Johnston C, Sim E, et al. Protective effect of apo epsilon 2 in Alzheimer’s disease. Oxford Project to Investigate Memory and Ageing (OPTIMA). Lancet (London, England). 1994;344: 473-474.
Rajan KB, Wilson RS, Skarupski KA, et al. Gene-behavior interaction of depressive symptoms and the apolipoprotein E {varepsilon}4 allele on cognitive decline. Psychosom Med. 2014 Feb;76(2):101-108. DOI: https://doi.org/10.1097/PSY.0000000000000029
Choi MJ, Lee HJ, Ham BJ, et al. Association between major depressive disorder and the -1438A/G polymorphism of the serotonin 2A receptor gene. Neuropsychobiology. 2004;49(1):38-41. DOI: https://doi.org/10.1159/000075337
Wang L, Ashley-Koch A, Steffens DC,et al. Impact of BDNF Val66Met and 5-HTTLPR polymorphism variants on neural substrates related to sadness and executive function. Genes Brain Behav. 2012;11(3):352-359. DOI: https://doi.org/10.1111/j.1601-183X.2012.00764.x
Parsons MJ, D’Souza UM, Arranz MJ, et al. The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol Psychiatry. 2004;56(6):406-410. DOI: https://doi.org/10.1016/j.biopsych.2004.06.020
Minov C, Baghai TC, Schule C, et al. Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett. 2001;303(2):119-122. DOI: https://doi.org/10.1016/S0304-3940(01)01704-9
Savitz JB, Drevets WC. Imaging phenotypes of major depressive disorder: genetic correlates. Neuroscience. 2009;164(1):300-330. DOI: https://doi.org/10.1016/j.neuroscience.2009.03.082
Homberg JR, Molteni R, Calabrese F, et al. The serotonin-BDNF duo: developmental implications for the vulnerability to psychopathology. Neurosci Biobehav Rev. 2014 Jun;43:35-47. DOI: https://doi.org/10.1016/j.neubiorev.2014.03.012
Harkness KL, Strauss J, Michael Bagby R, et al. Interactions between childhood maltreatment and brain-derived neurotrophic factor and serotonin transporter polymorphisms on depression symptoms. Psychiatry Res. 2015; 229(1-2):609-612. DOI: https://doi.org/10.1016/j.psychres.2015.04.040
Kostic M, Canu E, Agosta F, et al. The Cumulative Effect of Genetic Polymorphisms on Depression and Brain Structural Integrity. Hum Brain Mapp. 2016;37(6):2173-2184. DOI: https://doi.org/10.1002/hbm.23165